Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Nektar Therapeutics announced results of its phase II proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma at the 66th ASH Annual Meeting and Exposition in San Diego.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial. 
Positive high-level results from the Tropion-Breast02 phase III trial showed Datroway (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival compared to investigator’s choice of chemotherapy as first-line treatment for patients with locally recurrent inoperable or metastatic triple-negative breast cancer for whom immunotherapy was not an option.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login